1551PD - Role of temporary ovarian suppression obtained with GnRH analog in reducing premature ovarian failure (POF) induced by chemotherapy in premenopausal...

Date 30 September 2012
Event ESMO Congress 2012
Session Supportive and palliative care: Controlling disease and treatment side-effects
Topics Complications of Treatment
Presenter Lucia Del Mastro
Authors L. Del Mastro1, A. Levaggi1, F. Poggio2, S. Giraudi2, C. Bighin2, A. D'Alonzo2, M. Lambertini2, P. Pronzato2, P. Bruzzi3
  • 1IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 2Oncologia Medica A, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 3Clinical Epidemiology, IST-San Martino, 16125 - Genoa/IT



premenopausal cancer patients treated with chemotherapy (CT) are at risk of POF. The role of GnRHa in the prevention of CT-induced POF is still controversial. We performed a pooled analysis of randomized studies that evaluated the role of GnRHa as strategy to prevent POF.


studies were retrieved by searching the PubMed database and the proceedings of major conferences. Odds ratios (OR) and 95% CIs for CT induced POF were extracted from each trial and averaged to obtain pooled estimates using an inverse-variance model.


we included in the meta-analysis 7 randomized trials involving 745 premenopausal women randomly assigned to receive chemotherapy or chemotherapy + GnRHa: five trials were carried out in breast cancer patients and two trials in patients with lymphoma. The pooled OR estimate for CT induced POF was 0.46 (95% CI, 0.3-0.72).


temporary ovarian suppression obtained with the use of GnRH analogues reduces the incidence of chemotherapy induced POF in premenopausal cancer patients.


All authors have declared no conflicts of interest.